Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 2285

Next Previous
X
Search
Drug Profile

SHR 2285

Alternative Names: Factor-XI-antagonist; SHR-2285

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Atridia; Jiangsu Hengrui Medicine Co.; Shanghai Hengrui Pharmaceutical
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Venous thromboembolism
  • No development reported Thrombosis

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in Australia (PO, Tablet)
  • 15 Jun 2022 Jiangsu HengRui Medicine completes a phase I trial in healthy volunteers in China (PO, Tablet) (NCT04945616)
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in China (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top